99 related articles for article (PubMed ID: 28436708)
1. A novel in vitro ELISA for estimation of glycoprotein content in human rabies vaccines.
Aavula SM; Abhinay G; Nimmagadda SV; Maithal K
J Immunoassay Immunochem; 2017; 38(4):400-410. PubMed ID: 28436708
[TBL] [Abstract][Full Text] [Related]
2. Recombinant diabody-based immunocapture enzyme-linked immunosorbent assay for quantification of rabies virus glycoprotein.
Nimmagadda SV; Aavula SM; Biradhar N; Rao VS; Shanmugham R; Chandran D; Thirumeni N; Singanallur NB; Villuppanoor SA
Clin Vaccine Immunol; 2010 Aug; 17(8):1261-8. PubMed ID: 20573881
[TBL] [Abstract][Full Text] [Related]
3. A relevant in vitro ELISA test in alternative to the in vivo NIH test for human rabies vaccine batch release.
Gibert R; Alberti M; Poirier B; Jallet C; Tordo N; Morgeaux S
Vaccine; 2013 Dec; 31(50):6022-9. PubMed ID: 24161572
[TBL] [Abstract][Full Text] [Related]
4. Development of a relative potency test using ELISA for human rabies vaccines.
Wang Z; Sun Y; Wu X; Carroll DS; Lv W; You L; Ji Y; Shi J; Yan J; Xu G; Meng S
Biologicals; 2018 Sep; 55():59-62. PubMed ID: 29970288
[TBL] [Abstract][Full Text] [Related]
5. A novel site-II directed glycoprotein estimation ELISA to aid rabies vaccine manufacture for veterinary and human use.
Abhinay G; Dessain S; Srikanth A; Senthilkumar RL; Vidyasagar P; Praveen A; Chandrasekhar Reddy RV; Swapna Reddy E; Rajendra L
Vaccine; 2014 Jan; 32(2):209-13. PubMed ID: 24262315
[TBL] [Abstract][Full Text] [Related]
6. In Vitro ELISA Test to Evaluate Rabies Vaccine Potency.
Jallet C; Tordo N
J Vis Exp; 2020 May; (159):. PubMed ID: 32449742
[TBL] [Abstract][Full Text] [Related]
7. Standardization of an enzyme immunoassay for the in vitro potency assay of inactivated tissue culture rabies vaccines: determination of the rabies virus glycoprotein with polyclonal antisera.
Thraenhart O; Ramakrishnan K
J Biol Stand; 1989 Oct; 17(4):291-309. PubMed ID: 2613705
[TBL] [Abstract][Full Text] [Related]
8. Development of competitive inhibition ELISA as an effective potency test to analyze human rabies vaccines and assessment of the antigenic epitope of rabies glycoprotein.
Soni D; Sahoo I; Mallya AD; Kamthe P; Sahai A; Goel SK; Kulkarni PS; Dhere RM
J Immunol Methods; 2021 May; 492():112939. PubMed ID: 33309752
[TBL] [Abstract][Full Text] [Related]
9. A time-resolved fluoroimmunoassay to assay the rabies virus glycoprotein: application for estimation of human rabies vaccine potency.
Lin G; Chen S; Zhao H; Liang J; Deng Q; Liang R; Guo X; Chen Z; Chen B; Liu T; Wu Y
Sci Rep; 2017 Aug; 7(1):7288. PubMed ID: 28779162
[TBL] [Abstract][Full Text] [Related]
10. Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA - Results of an international collaborative study.
Morgeaux S; Poirier B; Ragan CI; Wilkinson D; Arabin U; Guinet-Morlot F; Levis R; Meyer H; Riou P; Shaid S; Volokhov D; Tordo N; Chapsal JM
Vaccine; 2017 Feb; 35(6):966-971. PubMed ID: 28081969
[TBL] [Abstract][Full Text] [Related]
11. Verification of the rabies virus glycoprotein lower limit of immunogenicity by serological assay.
Moreira WC; Machado NS; Freitas JFS; Almeida AECC; Moura WC
J Virol Methods; 2019 Feb; 264():31-37. PubMed ID: 30448319
[TBL] [Abstract][Full Text] [Related]
12. G-protein based ELISA as a potency test for rabies vaccines.
Chabaud-Riou M; Moreno N; Guinchard F; Nicolai MC; Niogret-Siohan E; Sève N; Manin C; Guinet-Morlot F; Riou P
Biologicals; 2017 Mar; 46():124-129. PubMed ID: 28214171
[TBL] [Abstract][Full Text] [Related]
13. Multicenter comparative study of a new ELISA, PLATELIA RABIES II, for the detection and titration of anti-rabies glycoprotein antibodies and comparison with the rapid fluorescent focus inhibition test (RFFIT) on human samples from vaccinated and non-vaccinated people.
Feyssaguet M; Dacheux L; Audry L; Compoint A; Morize JL; Blanchard I; Bourhy H
Vaccine; 2007 Mar; 25(12):2244-51. PubMed ID: 17224214
[TBL] [Abstract][Full Text] [Related]
14. A novel ELISA for quantification of glycoprotein in human rabies vaccines using a clinically proven virus neutralizing human monoclonal antibody.
Gairola S; Gautam M; Waghmare S
Hum Vaccin Immunother; 2020 Aug; 16(8):1857-1865. PubMed ID: 31971485
[TBL] [Abstract][Full Text] [Related]
15. A simple immuno-capture ELISA to estimate rabies viral glycoprotein antigen in vaccine manufacture.
Nagarajan T; Reddy GS; Mohana Subramanian B; Rajalakshmi S; Thiagarajan D; Tordo N; Jallet C; Srinivasan VA
Biologicals; 2006 Mar; 34(1):21-7. PubMed ID: 16188454
[TBL] [Abstract][Full Text] [Related]
16. Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing.
Rooijakkers EJ; Uittenbogaard JP; Groen J; Osterhaus AD
J Virol Methods; 1996 Apr; 58(1-2):111-9. PubMed ID: 8783156
[TBL] [Abstract][Full Text] [Related]
17. In vitro rabies vaccine potency appraisal by ELISA: advantages of the immunocapture method with a neutralizing anti-glycoprotein monoclonal antibody.
Perrin P; Morgeaux S; Sureau P
Biologicals; 1990 Oct; 18(4):321-30. PubMed ID: 2285504
[TBL] [Abstract][Full Text] [Related]
18. Use of ELISA for in vitro potency test of rabies vaccines for animal use.
Gamoh K; Senda M; Itoh O; Muramatsu M; Hirayama N; Koike R; Endoh YS; Minamoto N
Biologicals; 1996 Jun; 24(2):95-101. PubMed ID: 8889055
[TBL] [Abstract][Full Text] [Related]
19. Measurement of rabies virus N protein in rabies vaccines.
Montaño-Hirose JA; Lafage M; Lafon M
Res Virol; 1995; 146(3):217-24. PubMed ID: 7481094
[TBL] [Abstract][Full Text] [Related]
20. An ELISA-based antigenicity test of rabies recombinant glycoprotein cannot predict its protective potency in vivo.
Volokhov DV; Fry AM; Furtak V; Jones RM; Musiychuk K; Norikane J; Green BJ; Srinivas GB; Streatfield SJ; Yusibov V
Mol Cell Probes; 2022 Jun; 63():101815. PubMed ID: 35364264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]